Aware Super Pty Ltd as trustee of Aware Super Takes $1.76 Million Position in Elevance Health, Inc. (NYSE:ELV)

Aware Super Pty Ltd as trustee of Aware Super purchased a new position in Elevance Health, Inc. (NYSE:ELV - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 4,781 shares of the company's stock, valued at approximately $1,764,000.

A number of other large investors also recently bought and sold shares of the business. Tobam lifted its position in Elevance Health by 6.6% during the fourth quarter. Tobam now owns 434 shares of the company's stock valued at $160,000 after acquiring an additional 27 shares during the last quarter. Jacobi Capital Management LLC boosted its position in shares of Elevance Health by 3.2% in the 4th quarter. Jacobi Capital Management LLC now owns 882 shares of the company's stock worth $325,000 after purchasing an additional 27 shares in the last quarter. Austin Private Wealth LLC grew its stake in Elevance Health by 1.5% during the 4th quarter. Austin Private Wealth LLC now owns 1,996 shares of the company's stock worth $736,000 after buying an additional 29 shares during the last quarter. Quent Capital LLC raised its stake in Elevance Health by 2.1% in the fourth quarter. Quent Capital LLC now owns 1,488 shares of the company's stock valued at $549,000 after buying an additional 30 shares during the last quarter. Finally, RDA Financial Network boosted its holdings in Elevance Health by 0.5% in the fourth quarter. RDA Financial Network now owns 6,384 shares of the company's stock worth $2,355,000 after acquiring an additional 32 shares in the last quarter. Institutional investors own 89.24% of the company's stock.

Insider Transactions at Elevance Health

In related news, CAO Ronald W. Penczek sold 443 shares of Elevance Health stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $415.13, for a total value of $183,902.59. Following the completion of the sale, the chief accounting officer now owns 1,847 shares in the company, valued at approximately $766,745.11. This trade represents a 19.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total value of $1,388,635.20. Following the transaction, the executive vice president now owns 10,116 shares of the company's stock, valued at approximately $4,008,970.80. This represents a 25.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.29% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Argus upgraded shares of Elevance Health from a "hold" rating to a "buy" rating and set a $450.00 price objective on the stock in a report on Monday, March 17th. Truist Financial upped their price target on shares of Elevance Health from $480.00 to $510.00 and gave the company a "buy" rating in a research note on Friday, April 11th. Mizuho lifted their price objective on shares of Elevance Health from $455.00 to $505.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 9th. Stephens downgraded Elevance Health from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $520.00 to $440.00 in a research report on Wednesday, January 22nd. Finally, Barclays lifted their price target on Elevance Health from $501.00 to $512.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $508.81.

Elevance Health Price Performance

NYSE ELV traded down $15.92 during trading hours on Monday, reaching $408.61. The company's stock had a trading volume of 490,679 shares, compared to its average volume of 1,440,502. The firm has a market capitalization of $92.50 billion, a price-to-earnings ratio of 15.96, a P/E/G ratio of 1.18 and a beta of 0.77. Elevance Health, Inc. has a 1-year low of $362.21 and a 1-year high of $567.26. The company's 50-day moving average is $416.77 and its two-hundred day moving average is $409.81. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50.

Elevance Health (NYSE:ELV - Get Free Report) last announced its earnings results on Thursday, January 23rd. The company reported $3.84 EPS for the quarter, beating analysts' consensus estimates of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. On average, equities analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 25th. Shareholders of record on Monday, March 10th were issued a $1.71 dividend. This represents a $6.84 annualized dividend and a yield of 1.67%. This is a positive change from Elevance Health's previous quarterly dividend of $1.63. The ex-dividend date was Monday, March 10th. Elevance Health's payout ratio is presently 26.71%.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.